What is CJC-1295 / Ipa (No DAC)?

Overview

CJC-1295 is a modified GHRH(1-29) analog stabilized by four amino-acid substitutions. Those substitutions block the enzymatic degradation that typically chews through native GHRH in minutes, producing a peptide with a measurably longer half-life. The mechanism researchers care about: CJC-1295 triggers the pituitary’s own GH release machinery rather than supplying exogenous GH. Published data show preserved diurnal GH pulsatility — important because tonic GH exposure causes receptor desensitization, while pulsatile exposure does not. IF the research question is endogenous GH-axis modulation with preserved pulsatility, THEN CJC-1295 is the GHRH analog with the cleanest published pharmacology. SO it belongs in protocols studying IGF-1 response, sleep-wave modulation, or GH/IGF-1-axis physiology. ≥99% purity, batch-tested, CoA included.

Research areas

• GHRH receptor activation

  <p>Selective agonist at pituitary GHRH receptors. Stimulates synthesis and pulsatile release of endogenous growth hormone without displacing natural regulation.</p>

• Half-life characteristics

  <p>Four amino-acid substitutions protect the peptide from DPP-IV cleavage. Plasma half-life is measured in hours rather than minutes, supporting once-daily protocols.</p>

• Pairing with GHRPs

  <p>Research protocols frequently combine CJC-1295 with a ghrelin mimetic (Ipamorelin, GHRP-2) for synergistic GH release through parallel receptor pathways.</p>

• Administration

  <p>Subcutaneous injection is standard. Reconstitute with bacteriostatic water; refrigerate reconstituted solution and use within 30 days.</p>

Published research

• Ghrelin is a growth-hormone-releasing acylated peptide from stomach

  PMID 10604470 — PubMed

• GHRP-6 is able to stimulate cortisol and ACTH release in patients…

  PMID 12809173 — PubMed

• Growth hormone-releasing effect of oral growth hormone…

  PMID 7581965 — PubMed

• Growth hormone-releasing peptides

  PMID 9186261 — PubMed

• I and IGF binding protein concentrations to growth hormone (GH…

  PMID 19351723 — PubMed

• induced ACTH release in patients with addison's disease: effect of…

  PMID 12739742 — PubMed

Storage & handling

Lyophilized CJC-1295 / Ipa (No DAC)is stored at –20 °C protected from light. Once reconstituted with bacteriostatic water, store at 2–8 °C and use within 30 days for maximum stability.

Frequently asked questions

What is CJC-1295 / Ipa (No DAC)?

CJC-1295 / Ipa (No DAC) (CJC-1295) is a research compound studied in the area of longevity & anti-aging. A growth-hormone-releasing hormone analog. Studied for its stable, long-acting stimulation of endogenous GH pulses without desensitization.

What is the CAS number of CJC-1295 / Ipa (No DAC)?

The CAS registry number of CJC-1295 / Ipa (No DAC) is 863288-34-0.

How should CJC-1295 / Ipa (No DAC) be stored?

Lyophilized CJC-1295 / Ipa (No DAC) should be stored at –20 °C protected from light. Once reconstituted with bacteriostatic water, store at 2–8 °C and use within 30 days for maximum stability.

How is the purity of CJC-1295 / Ipa (No DAC) verified?

Every Woosh Labs batch of CJC-1295 / Ipa (No DAC) is independently tested by third-party HPLC and mass spectrometry, with a batch-specific Certificate of Analysis published verifying ≥99% purity.

Is CJC-1295 / Ipa (No DAC) for human use?

No. CJC-1295 / Ipa (No DAC) sold by Woosh Labs is strictly for in-vitro laboratory research by qualified professionals. It is not for human or veterinary use of any kind.